The Four Key Trends In Pharmaceutical Alliances
Executive Summary
As the worst threats of managed care receded, the industry saw an explosion in the number of available, innovative late-stage drugs, both from biotechs and from mid-sized companies unable to sell them on their own. Genomics and combinatorial chemistry burst onto the R&D scene, generating a huge wealth of targets and compounds. The result has been a sudden return to the roots of the drug industry: finding and selling innovative branded products.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.